This segment focuses on the research, development, and clinical evaluation of novel immunotherapies for cancer treatment. Sensei Biotherapeutics utilizes its proprietary ImmunoPhage platform, which employs bacteriophage to stimulate a targeted immune response against tumors. Research and development activities include preclinical studies, clinical trials, and the engineering of ImmunoPhage product candidates. The company is also developing nanobody technology to modulate the tumor microenvironment. The therapeutic areas covered include various solid tumors. The patient impact is aimed at improving outcomes for patients with PD-(L)1 resistant cancers and other advanced solid tumors. Sensei's market positioning is as a clinical-stage biotechnology company with a focus on next-generation therapeutics. Future opportunities include expanding the pipeline and advancing clinical trials. Regulatory and clinical aspects involve navigating FDA approval processes and conducting clinical trials. Partnerships and collaborations are key to advancing research and development, as demonstrated by collaborations with academic institutions.